Hospital Universitario Puerta de Hierro -ko ikertzaileekin lankidetzan egindako argitalpenak (21)

2020

  1. The urgent need for integrated science to fight COVID-19 pandemic and beyond

    Journal of Translational Medicine, Vol. 18, Núm. 1

2019

  1. Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort

    Liver International, Vol. 39, Núm. 1, pp. 90-97

  2. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

    Nature Communications, Vol. 10, Núm. 1

2017

  1. Quorum sensing network in clinical strains of A. baumannii: AidA is a new quorum quenching enzyme

    PLoS ONE, Vol. 12, Núm. 3

  2. Response to bile salts in clinical strains of Acinetobacter baumannii lacking the adeABC efflux pump: Virulence associated with quorum sensing

    Frontiers in Cellular and Infection Microbiology, Vol. 7, Núm. MAY

2014

  1. A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility

    Arthritis Research and Therapy, Vol. 16, Núm. 1

  2. Epidemiologic and clinical impact of acinetobacter baumannii colonization and infection: A reappraisal

    Medicine (United States), Vol. 93, Núm. 5, pp. 202-210

2013

  1. The Systemic Lupus Erythematosus IRF5 Risk Haplotype Is Associated with Systemic Sclerosis

    PLoS ONE, Vol. 8, Núm. 1

2012

  1. Novel identification of the IRF7 region as an anticentromere autoantibody propensity locus in systemic sclerosis

    Annals of the Rheumatic Diseases, Vol. 71, Núm. 1, pp. 114-119

  2. The autoimmune disease-associated IL2RA locus is involved in the clinical manifestations of systemic sclerosis

    Genes and Immunity, Vol. 13, Núm. 2, pp. 191-196

2011

  1. No evidence for association between the CCR5/Delta32CCR5 polymorphism and systemic sclerosis

    Clinical and Experimental Rheumatology

2006

  1. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplantation recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus

    Liver Transplantation, Vol. 12, Núm. 10, pp. 1464-1472

2005

  1. Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus

    Transplantation Proceedings

2003

  1. Cardiovascular morbidity and obesity in adult liver transplant recipients

    Transplantation Proceedings

  2. Chronic renal dysfunction after liver transplantation in adult patients: Prevalence, risk factors, and impact on mortality

    Transplantation Proceedings

  3. De novo malignancies in liver transplantation

    Transplantation Proceedings

  4. Effectiveness and safety of mycophenolate mofetil as monotherapy in liver transplantation

    Transplantation Proceedings

  5. Effectiveness of low-dose intramuscular anti-VHB immune globulin in the prophylaxis of viral B hepatitis reinfection after liver transplantation: Preliminary report

    Transplantation Proceedings

  6. Recurrence of primary biliary cirrhosis after liver transplantation

    Transplantation Proceedings

  7. Usefulness of chemotherapy as prophylaxis of tumor recurrence after liver transplantation in advanced hepatocellular carcinomas

    Transplantation Proceedings